Health & Fitness
Health and Fitness
Health and Fitness
Fri, May 20, 2011
Thu, May 19, 2011 
HALIFAX, May 19 /CNW/ - Immunovaccine Inc., (TSX-V:IMV) a clinical stage vaccine development company, is pleased to provide an update on recent clinical research, business development and corporate activities.
Clinical Research Update
Immunovaccine has completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for DPX-Survivac. DPX-Survivac is a therapeutic cancer vaccine candidate that uses Survivin-based antigens (in-licensed from Merck KGaA) formulated in the DepoVax™ vaccine delivery platform. While DPX-Survivac has the potential to target at least nine different cancers, for this initial clinical trial the Company is developing DPX-Survivac to treat ovarian cancer.
In preclinical studies, DPX-Survivac was found to significantly enhance immune response over the control formulation used in previous clinical trials. The Company is completing the remaining safety studies required for the IND filing for clearance to begin human clinical trials.
Signs Research Partnership with CIMAB S.A.
Immunovaccine announced today that it has signed a research agreement with Cuban-based CIMAB S.A. In the agreement, the CIMAvax-EGF peptide antigen will be formulated in Immunovaccine's DepoVax™ delivery system to potentially enhance the immunogenicity of a novel therapeutic vaccine candidate.
CIMAB S.A. is devoted to the commercialization of biopharmaceutical products for the Cuban market and abroad, especially monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related to the immune system. CIMAB S.A. is the exclusive representative for the commercialization of the products and services of the Center of Molecular Immunology (CIM). In July 2008, CIM received approval from the Cuban regulatory authorities for a lung cancer vaccine, targeting epidermal growth factor (EGF), a protein that signals cancer cells to grow and divide uncontrollably.
Retains The Equicom Group for Strategic Investor Relations Services
Effective May 16, 2011, Immunovaccine has retained The Equicom Group Inc. ("Equicom") to provide strategic investor relations services. Equicom provides strategic communications services to approximately 100 public companies across a diverse range of industries. Under the terms of the agreement, Immunovaccine will pay Equicom a monthly fee of $5,800 for select strategic communication services. The initial contract term is six months and commences immediately.
Neither Equicom nor any of its principals have an ownership interest, directly or indirectly, in Immunovaccine or its securities, nor has the Company granted Equicom or its principals any rights to acquire any such interests. Equicom is a wholly-owned subsidiary of TMX Group Inc.
About Immunovaccine Inc.
Immunovaccine Inc. (TSX-V:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The Company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. [ www.imvaccine.com ]
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
